Biovail Presses Forward With CNS Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian drug maker is planning to launch Staccato loxapine and embark on an ambitious clinical program for pimavanserin in 2011.
You may also be interested in...
Is Neurotech's Search For Highly-Focused Targets Holding Up Drug Development In The Field?
The issue of whether a start-up should know its compound's mechanism of action before it knocks on a VC's door became an ongoing topic of conversation at the Neurotech Investing conference in Boston.
Is Neurotech's Search For Highly-Focused Targets Holding Up Drug Development In The Field?
The issue of whether a start-up should know its compound's mechanism of action before it knocks on a VC's door became an ongoing topic of conversation at the Neurotech Investing conference in Boston.
Deals Of The Week: Pfizer/GSK/Global Alliance, Ipsen/GTx, Biovail/Cortex ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com